Article ; Online: Dyslipidaemia and mortality in COVID-19 patients: a meta-analysis.
QJM : monthly journal of the Association of Physicians
2021 Volume 114, Issue 6, Page(s) 390–397
Abstract: ... patients with pre-existing dyslipidaemia.: Design: Systematic review and meta-analysis.: Methods ... infected by the SARS-CoV-2 remain unclear.: Aim: To assess the prevalence and mortality risk in COVID-19 ... to 31 January 2021, reporting data on dyslipidaemia among COVID-19 survivors and non-survivors ...
| Abstract | Background: The prevalence and prognostic implications of pre-existing dyslipidaemia in patients infected by the SARS-CoV-2 remain unclear. Aim: To assess the prevalence and mortality risk in COVID-19 patients with pre-existing dyslipidaemia. Design: Systematic review and meta-analysis. Methods: Preferred reporting items for systematic reviews and meta-analyses guidelines were followed in abstracting data and assessing validity. We searched MEDLINE and Scopus to locate all the articles published up to 31 January 2021, reporting data on dyslipidaemia among COVID-19 survivors and non-survivors. The pooled prevalence of dyslipidaemia was calculated using a random-effects model and presenting the related 95% confidence interval (CI), while the mortality risk was estimated using the Mantel-Haenszel random-effect models with odds ratio (OR) and related 95% CI. Statistical heterogeneity was measured using the Higgins I2 statistic. Results: Of about 18 studies, enrolling 74 132 COVID-19 patients (mean age 70.6 years), met the inclusion criteria and were included in the final analysis. The pooled prevalence of dyslipidaemia was 17.5% of cases (95% CI: 12.3-24.3%, P < 0.0001), with high heterogeneity (I2 = 98.7%). Pre-existing dyslipidaemia was significantly associated with higher risk of short-term death (OR: 1.69, 95% CI: 1.19-2.41, P = 0.003), with high heterogeneity (I2 = 88.7%). Due to publication bias, according to the Trim-and-Fill method, the corrected random-effect ORs resulted 1.61, 95% CI 1.13-2.28, P < 0.0001 (one studies trimmed). Conclusion: Dyslipidaemia represents a major comorbidity in about 18% of COVID-19 patients but it is associated with a 60% increase of short-term mortality risk. |
|||||
|---|---|---|---|---|---|---|
| MeSH term(s) | Aged ; COVID-19 ; Comorbidity ; Dyslipidemias/epidemiology ; Humans ; Prevalence ; SARS-CoV-2 | |||||
| Language | English | |||||
| Publishing date | 2021-04-06 | |||||
| Publishing country | England | |||||
| Document type | Journal Article ; Meta-Analysis ; Systematic Review | |||||
| ZDB-ID | 1199985-8 | |||||
| ISSN | 1460-2393 ; 0033-5622 ; 1460-2725 | |||||
| ISSN (online) | 1460-2393 | |||||
| ISSN | 0033-5622 ; 1460-2725 | |||||
| DOI | 10.1093/qjmed/hcab071 | |||||
| Shelf mark |
|
|||||
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
| Ua VI Zs.131: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.